CAS 247062-33-5

abaloparatide

Description:

Abaloparatide is a synthetic peptide that functions as a parathyroid hormone-related peptide (PTHrP) analog. It is primarily used in the treatment of osteoporosis, particularly in postmenopausal women at high risk for fractures. The substance promotes bone formation by stimulating osteoblast activity and enhancing calcium absorption in the intestines. Abaloparatide is characterized by its specific amino acid sequence, which mimics the action of natural parathyroid hormone, leading to increased bone mineral density. It is administered via subcutaneous injection and has a relatively short half-life, necessitating daily dosing. The compound is known for its potential to reduce the risk of vertebral and non-vertebral fractures, making it a valuable therapeutic option in osteoporosis management. Additionally, its safety profile includes common side effects such as nausea, dizziness, and injection site reactions. Overall, abaloparatide represents a significant advancement in osteoporosis treatment, offering a targeted approach to enhancing bone health.

Abaloparatide

CAS: 247062-33-5

The pTHrP-analog abaloparatide (BIM-44058) promoting bone growth has been developed for the treatment of osteoporosis.

Formula: C₁₇₄H₃₀₀N₅₆O₄₉

Purity: 96.2%

Color and Shape: White Whitish Powder

Molecular weight: 3960.64

Ref: 01-4105586

Abaloparatide

CAS: 247062-33-5

Abaloparatide (BA 058) is a selective PTHR1 analog that promotes bone growth and may be researched for osteoporosis.

Formula: C₁₇₄H₃₀₀N₅₆O₄₉

Color and Shape: Solid

Molecular weight: 3960.59

Ref: TM-T73690

Abaloparatide

CAS: 247062-33-5

Formula: C₁₇₄H₃₀₀N₅₆O₄₉·C₂H₄O₂

Molecular weight: 3960.66 60.05

Ref: 4Z-PA-421001

Abaloparatide acetate

CAS: 247062-33-5

Abaloparatide acetate is a peptide hormone that belongs to the calcitonin family. It is an analog of human calcitonin, which is a hormone that regulates bone metabolism. Abaloparatide acetate has been shown to have long-term efficacy and potency in humans as well as in vitro methods. It also has favorable pharmacokinetics and can be administered by subcutaneous injection. Clinical studies have shown that abaloparatide acetate can reduce the rate of bone loss, increase bone mineral density, and reduce the risk of fractures in postmenopausal women with osteoporosis. The drug's mechanism of action is not fully understood, but it may act by inhibiting the formation of osteoclasts or increasing their apoptosis, which would result in decreased resorption of bone tissue.

Formula: C₁₇₄H₃₀₀N₅₆O₄₉

Purity: Min. 95%

Molecular weight: 3,961 g/mol

Ref: 3D-XJA06233